Clinico-pharmacological aspects of different hormone treatments

This publication has 9 references indexed in Scilit:

• Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer
  Journal of Clinical Oncology, 1999
• Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study
  European Journal Of Cancer, 1999
• Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.
  Endocrine-Related Cancer, 1999
• Cross-resistance to different aromatase inhibitors in breast cancer treatment.
  Endocrine-Related Cancer, 1999
• The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
  British Journal of Cancer, 1998
• Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma
  Cancer, 1998
• Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
  Journal of Clinical Oncology, 1998
• Mechanisms of action of endocrine treatment in breast cancer
  Critical Reviews in Oncology/Hematology, 1995
• Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
  The Lancet, 1995